Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer (Q37452747)

20 August 2017

Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer (English)

1 reference

20 August 2017

1

Dawn L Hershman

1 reference

20 August 2017

6

Alfred I Neugut

1 reference

20 August 2017

Donna L Buono

2

1 reference

20 August 2017

Jennifer Malin

series ordinal

3

1 reference

20 August 2017

Russell McBride

series ordinal

4

1 reference

20 August 2017

Wei Yann Tsai

series ordinal

5

1 reference

20 August 2017

language of work or name

English

0 references

publication date

10 November 2009

1 reference

Journal of the National Cancer Institute

20 August 2017

1 reference

20 August 2017

101

1 reference

20 August 2017

23

1 reference

20 August 2017

1633-1641

1 reference

Retrospective review of hemoglobin and/or hematocrit levels with occurrence of thrombosis in cancer patients treated with erythropoiesis stimulating agents

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2786918

Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2786918

Evaluation of trends in the cost of initial cancer treatment

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2786918

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2786918

Efficacy and safety of epoetin alfa in critically ill patients

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2786918

Erythropoietin or Darbepoetin for patients with cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2786918

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2786918

Outpatient gatifloxacin therapy and dysglycemia in older adults

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2786918

Oral erythromycin and the risk of sudden death from cardiac causes

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2786918

Postmarketing surveillance for drug safety: surely we can do better

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2786918

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2786918

Measuring complications of cancer treatment using the SEER-Medicare data

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2786918

Development of a comorbidity index using physician claims data

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2786918

Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2786918

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2786918

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2786918

Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2786918

Scientific publishing. Echoing other cases, NEJM says Vioxx Safety data withheld

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2786918

The lessons of Vioxx--drug safety and sales

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2786918

Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2786918

Potential for cancer related health services research using a linked Medicare-tumor registry database.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2786918

Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies

2 September 2018

1 reference

12 December 2020

Reform of drug regulation--beyond an independent drug-safety board

1 reference

12 December 2020

Supraclavicular radiation for breast cancer does not increase the 10-year risk of stroke

1 reference

12 December 2020

Late gastrointestinal toxicity after radiation for prostate cancer

1 reference

12 December 2020

Medicare and erythropoietin

1 reference

12 December 2020

Radiation therapy, cardiac risk factors, and cardiac toxicity in early-stage breast cancer patients

1 reference

12 December 2020

Weighing the hazards of erythropoiesis stimulation in patients with cancer

1 reference

12 December 2020

Gender differences in age-related physiological changes and some diseases

1 reference

12 December 2020

Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

Assessing illness severity: does clinical judgment work?

1 reference

12 December 2020

Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy

1 reference

12 December 2020

Identifiers

DOI

10.1093/JNCI/DJP387

1 reference

20 August 2017

1 reference

20 August 2017

1 reference